We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Van Andel Institute and Spectrum Health Form Joint Venture

By Labmedica staff writers
Posted on 26 Mar 2007
Spectrum Health (Grand Rapids, MI, USA) and Van Andel Institute (VAI; Grand Rapids, MI, USA) have announced a US$6 million joint venture that will offer 21st century molecular technologies for investigation of complex diseases like cancer, heart disease, mental illness, and other conditions at the DNA, RNA, and protein levels.

The Center for Molecular Medicine (CMM), which is being created by these two companies, will provide West Michigan with a laboratory that will aid in early diagnoses and enhance personalized medicine. More...
The Center will also attract new opportunities for diagnostics and pharmaceutical companies to conduct trials in a medical and clinical research environment.

Located in the Grand Valley State University (GVSU) Cook-DeVos Center for Health Studies, the CMM combines Spectrum Health's clinical, laboratory, and research resources, and VAI's research expertise and intellectual property with the latest in molecular biological technology.

"To fulfill the mission of the Institute, we must move our findings from the research laboratory to the clinical laboratory. The Center for Molecular Medicine will allow us to do this in an accelerated fashion and positively impact human health,” said David Van Andel, chairman and CEO of Van Andel Institute. We have the research expertise and Spectrum Health has a large patient population which allows us to apply what we're learning directly into the clinical setting.”

"The Center for Molecular Medicine is an investment in the future of health care,” said Richard C. Breon, president and CEO, Spectrum Health. "It accelerates the drive toward personalized medicine--the tailoring of treatment based on molecular make-up.”


Related Links:
Spectrum Health
Center for Molecular Medicine

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Uric Acid Meter
PA-16
New
Francisella Tularensis Test
TULAREMIA VIRCLIA IgG+IgM MONOTEST
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: Switching to an experimental drug after liquid biopsy detection of breast cancer recurrence can improve outcomes (Photo courtesy of Shutterstock)

Treatment Switching Guided by Liquid Biopsy Blood Tests Improves Outcomes for Breast Cancer Patients

Standard treatment for patients with advanced estrogen receptor (ER)-positive, HER2-negative breast cancer, a subtype driven by estrogen receptors that fuel tumor growth, often involves aromatase inhibitors,... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.